FollowMyHealth Patient Portal

Daniel Morgensztern, MD

Associate Professor, Medicine
Division of Oncology
Section of Medical Oncology

Specialty Areas

Oncology
Lung Cancer
Medical Oncology
Thoracic Oncology
Esophageal Cancer

Board Certifications

Oncology
Internal Medicine

Hospital Affiliations

Barnes-Jewish Hospital

Areas of Clinical Interest

Medical oncology, lung cancer

  • Maps & Directions
  • Education
  • Publication & Research

Maps & Directions

Maps & Directions

Siteman Cancer Center - South County

5225 MidAmerica Plaza
St. Louis, MO 63129
Phone: 314-747-7222

Center for Advanced Medicine
Siteman Cancer Center

4921 Parkview Place
St. Louis, MO 63110
Phone: 314-747-7222

Suite: B
Floor: 7
Office Phone: (314) 747-7222
Additional Phone: (800) 600-3606

Education

Education

Medical Degree: Fundacao Tecnico-Educacional Souza Marques, Brazil 1995
Residency, Internal Medicine: University of Miami Hospital, Miami, FL 2001
Fellowship, Hematology-Oncology: University of Miami, Miami, FL 2004
Residency, Internal Medicine and Hematology: State University of Rio de Janeiro, Brazil 1998

Publication & Research

Publication & Research

Percutaneous Image-Guided Ablation in the Treatment of Osseous Metastases from Non-small Cell Lung Cancer.
Ma Y, Wallace AN, Waqar SN, Morgensztern D, Madaelil TP, Tomasian A, Jennings JW
Cardiovasc Intervent Radiol. 2017 Dec 4; doi: 10.1007/s00270-017-1843-6.

PMID:
    29204695
    [PubMed - as supplied by publisher]
Related citations


<i>nab</i>-paclitaxel/carboplatin induction in squamous NSCLC: longitudinal quality of life while on chemotherapy.
Thomas M, Spigel DR, Jotte RM, McCleod M, Socinski MA, Page RD, Gressot L, Knoble J, Juan O, Morgensztern D, Isla D, Kim ES, West H, Ko A, Ong TJ, Trunova N, Gridelli C
Lung Cancer (Auckl). 2017; 8207-216. doi: 10.2147/LCTT.S138570.

PMID:
    29138610
    [PubMed]
Related citations


Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas.
Oronsky B, Ma PC, Morgensztern D, Carter CA
Neoplasia. 2017 Dec; 19(12)991-1002. doi: 10.1016/j.neo.2017.09.002.

PMID:
    29091800
    [PubMed - in process]
Related citations


Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.
Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro Carpeño J, Wadsworth C, Melillo G, Jiang H, Huang Y, Dennis PA, Özgüroğlu M, PACIFIC Investigators.
N Engl J Med. 2017 Nov 16; 377(20)1919-1929. doi: 10.1056/NEJMoa1709937.

PMID:
    28885881
    [PubMed - indexed for MEDLINE]
Related citations


Treatment advances in small cell lung cancer (SCLC).
Waqar SN, Morgensztern D
Pharmacol Ther. 2017 Dec; 18016-23. doi: 10.1016/j.pharmthera.2017.06.002.

PMID:
    28579387
    [PubMed - in process]
Related citations


Adjuvant Chemotherapy Is Associated With Improved Survival in Locally Invasive Node Negative Non-Small Cell Lung Cancer.
Ahmad U, Crabtree TD, Patel AP, Morgensztern D, Robinson CG, Krupnick AS, Kreisel D, Jones DR, Patterson GA, Meyers BF, Puri V
Ann Thorac Surg. 2017 Jul; 104(1)303-307. doi: 10.1016/j.athoracsur.2017.01.069.

PMID:
    28433225
    [PubMed - indexed for MEDLINE]
Related citations


Defining the Ideal Time Interval Between Planned Induction Therapy and Surgery for Stage IIIA Non-Small Cell Lung Cancer.
Samson P, Crabtree TD, Robinson CG, Morgensztern D, Broderick S, Krupnick AS, Kreisel D, Patterson GA, Meyers B, Puri V
Ann Thorac Surg. 2017 Apr; 103(4)1070-1075. doi: 10.1016/j.athoracsur.2016.09.053.

PMID:
    28110809
    [PubMed - indexed for MEDLINE]
Related citations


Precision medicine in lung cancer: the battle continues.
Waqar SN, Morgensztern D
J Thorac Dis. 2016 Nov; 8(11)2991-2993. doi: 10.21037/jtd.2016.11.46.

PMID:
    28066565
    [PubMed]
Related citations


MINI01.20: Interim Quality of Life (QoL) Results from ABOUND.sqm: nab-Paclitaxel/Carboplatin Induction Therapy in Squamous (SCC) NSCLC: Topic: Medical Oncology.
Thomas M, Page R, Gressot L, Daniel D, Morgensztern D, Levy B, Hussein M, Razaq M, Villaflor VM, Aix SP, Sivarajan K, Engel-Riedel W, Staib P, Ko A, Ong TJ, Trunova N, Spigel DR
J Thorac Oncol. 2016 Nov; 11(11S)S269. doi: 10.1016/j.jtho.2016.09.035.

PMID:
    27969468
    [PubMed - in process]
Related citations


ORAL02.01: Safety and Efficacy of Single-Agent Rovalpituzumab Tesirine, a DLL3-Targeted ADC, in Recurrent or Refractory SCLC: Topic: Medical Oncology.
Bauer TM, Spigel D, Ready N, Morgensztern D, Glisson BS, Byers LA, Burris H, Robert F, Strickland DK, Pietanza MC, Govindan R, Dylla SJ, Peng S, Rudin C
J Thorac Oncol. 2016 Nov; 11(11S)S252-S253. doi: 10.1016/j.jtho.2016.09.010.

PMID:
    27969444
    [PubMed - in process]
Related citations


Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study.
Rudin CM, Pietanza MC, Bauer TM, Ready N, Morgensztern D, Glisson BS, Byers LA, Johnson ML, Burris HA 3rd, Robert F, Han TH, Bheddah S, Theiss N, Watson S, Mathur D, Vennapusa B, Zayed H, Lally S, Strickland DK, Govindan R, Dylla SJ, Peng SL, Spigel DR, SCRX16-001 investigators.
Lancet Oncol. 2017 Jan; 18(1)42-51. doi: 10.1016/S1470-2045(16)30565-4.

PMID:
    27932068
    [PubMed - indexed for MEDLINE]
Related citations


Evolving Treatment Options for Lung Cancer.
Morgensztern D, Herbst RS
Hematol Oncol Clin North Am. 2017 Feb; 31(1)xiii-xiv. doi: 10.1016/j.hoc.2016.09.001.

PMID:
    27912837
    [PubMed - in process]
Related citations


Systemic Treatment of Brain Metastases.
Waqar SN, Morgensztern D, Govindan R
Hematol Oncol Clin North Am. 2017 Feb; 31(1)157-176. doi: 10.1016/j.hoc.2016.08.007.

PMID:
    27912831
    [PubMed - indexed for MEDLINE]
Related citations


Immunotherapy in Lung Cancer.
Du L, Herbst RS, Morgensztern D
Hematol Oncol Clin North Am. 2017 Feb; 31(1)131-141. doi: 10.1016/j.hoc.2016.08.004.

PMID:
    27912829
    [PubMed - indexed for MEDLINE]
Related citations


Immune checkpoint inhibition in patients with brain metastases.
Johanns T, Waqar SN, Morgensztern D
Ann Transl Med. 2016 Oct; 4(Suppl 1)S9.

PMID:
    27867977
    [PubMed]
Related citations


Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O'Brien M, Rao S, Hotta K, Leiby MA, Lubiniecki GM, Shentu Y, Rangwala R, Brahmer JR, KEYNOTE-024 Investigators.
N Engl J Med. 2016 Nov 10; 375(19)1823-1833.

PMID:
    27718847
    [PubMed - indexed for MEDLINE]
Related citations


Role for adjuvant chemotherapy in patients with resected small cell lung cancer.
Du L, Waqar SN, Morgensztern D
J Thorac Dis. 2016 Aug; 8(8)1891-2. doi: 10.21037/jtd.2016.07.15.

PMID:
    27618843
    [PubMed]
Related citations


Multimodality Therapy for NSCLC.
Du L, Waqar SN, Morgensztern D
Cancer Treat Res. 2016; 170151-63. doi: 10.1007/978-3-319-40389-2_7.

PMID:
    27535393
    [PubMed - indexed for MEDLINE]
Related citations


Adjuvant Chemotherapy for Patients with T2N0M0 NSCLC.
Morgensztern D, Du L, Waqar SN, Patel A, Samson P, Devarakonda S, Gao F, Robinson CG, Bradley J, Baggstrom M, Masood A, Govindan R, Puri V
J Thorac Oncol. 2016 Oct; 11(10)1729-35. doi: 10.1016/j.jtho.2016.05.022.

PMID:
    27287414
    [PubMed - indexed for MEDLINE]
Related citations


Nivolumab and Pembrolizumab for Non-Small Cell Lung Cancer.
Morgensztern D, Herbst RS
Clin Cancer Res. 2016 Aug 1; 22(15)3713-7. doi: 10.1158/1078-0432.CCR-15-2998.

PMID:
    27252413
    [PubMed - indexed for MEDLINE]
Related citations